Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial
Autor: | Gary Frost, Edward S. Chambers, Eleanor Cropp, M. A. Ghatei, Jeanne H. Bottin, Jonathan R. Swann, Heather E. Ford |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: |
Male
0301 basic medicine medicine.medical_treatment Appetite Medicine (miscellaneous) Gastric emptying Overweight IAUC incremental AUC Poultry Eating chemistry.chemical_compound GI gastrointestinal 0302 clinical medicine Fusarium Glucagon-Like Peptide 1 GAA guanidinoacetic acid Insulin media_common 2. Zero hunger Nutrition and Dietetics digestive oral and skin physiology Dipeptides Middle Aged Full Papers Postprandial Period Postprandial Metabonomics PYY peptide tyrosine-tyrosine Female Dietary Proteins medicine.symptom Adult medicine.medical_specialty media_common.quotation_subject Mycoprotein 030209 endocrinology & metabolism Satiation Biology T2DM type 2 diabetes mellitus Fungal Proteins Gastrointestinal Hormones Young Adult 03 medical and health sciences Appetite hormones Internal medicine 0702 Animal Production medicine Animals Humans Peptide YY Resting energy expenditure Obesity 030109 nutrition & dietetics Nutrition & Dietetics Appetite Regulation Behaviour Appetite and Obesity REE resting energy expenditure Endocrinology chemistry 1111 Nutrition And Dietetics Energy intake GLP-1 glucagon-like peptide-1 0908 Food Sciences |
Zdroj: | The British Journal of Nutrition |
Popis: | Dietary mycoprotein decreases energy intake in lean individuals. The effects in overweight individuals are unclear, and the mechanisms remain to be elucidated. This study aimed to investigate the effect of mycoprotein on energy intake, appetite regulation, and the metabolic phenotype in overweight and obese volunteers. In two randomised-controlled trials, fifty-five volunteers (age: 31 (95 % CI 27, 35) years), BMI: 28·0 (95 % CI 27·3, 28·7) kg/m2) consumed a test meal containing low (44 g), medium (88 g) or high (132 g) mycoprotein or isoenergetic chicken meals. Visual analogue scales and blood samples were collected to measure appetite, glucose, insulin, peptide tyrosine-tyrosine (PYY) and glucagon-like peptide-1 (GLP-1). Ad libitum energy intake was assessed after 3 h in part A (n 36). Gastric emptying by the paracetamol method, resting energy expenditure and substrate oxidation were recorded in part B (n 14). Metabonomics was used to compare plasma and urine samples in response to the test meals. Mycoprotein reduced energy intake by 10 % (280 kJ (67 kcal)) compared with chicken at the high content (P=0·009). All mycoprotein meals reduced insulin concentrations compared with chicken (incremental AUClow (IAUClow): −8 %, IAUCmedium: −12 %, IAUChigh: −21 %, P=0·004). There was no significant difference in glucose, PYY, GLP-1, gastric emptying rate and energy expenditure. Following chicken intake, paracetamol-glucuronide was positively associated with fullness. After mycoprotein, creatinine and the deamination product of isoleucine, α-keto-β-methyl-N-valerate, were inversely related to fullness, whereas the ketone body, β-hydroxybutyrate, was positively associated. In conclusion, mycoprotein reduces energy intake and insulin release in overweight volunteers. The mechanism does not involve changes in PYY and GLP-1. The metabonomics analysis may bring new understanding to the appetite regulatory properties of food. |
Databáze: | OpenAIRE |
Externí odkaz: |